Where Is the YCT-529 Data? The Male Pill Trial's Completion Date Has Passed

Published October 26, 2026 · Investigational · Not approved

YCT-529, from YourChoice Therapeutics, is the candidate most people mean by "the male pill." It's an investigational, non-hormonal daily pill and is not approved anywhere. Its most important study, the one designed to look at what the drug does to sperm, had a listed completion date of July 31, 2026. As of October 24, 2026, the registry still lists it as recruiting, and no results have been posted. Here's what's public and what isn't.

What the registry says

The study is NCT06542237 on ClinicalTrials.gov: an open-label, dose-escalation Phase 1b/2a trial of daily YCT-529 for 28, 90 or 180 days in healthy men who either plan a vasectomy or have decided not to father children. It started September 11, 2024 in New Zealand, with an estimated enrollment of 88. Its listed primary completion and completion dates are both July 31, 2026, and its status is "Recruiting."

What a passed date does, and doesn't, mean

A completion date on ClinicalTrials.gov is an estimate entered by the sponsor. Sponsors often update these dates late, and trials frequently run longer than planned for ordinary reasons such as slow enrollment or added cohorts. So a past date isn't evidence of a problem. It does mean the public record is out of date, and that the efficacy data people are waiting for isn't out yet. We haven't seen a public statement from YourChoice explaining the timeline.

What has been published

The only peer-reviewed human data is the Phase 1a trial: 16 men, single doses, published in Communications Medicine in 2025. It reported that single doses were well tolerated, with no reported effect on testosterone, sexual desire or mood. That study was not designed to measure sperm or prevent pregnancy. (For more background, see our YCT-529 explainer.)

New in October: a better way to make it

On October 20, 2026, the Journal of Organic Chemistry published a "second-generation synthesis" of YCT-529 from Gunda Georg's lab at the University of Minnesota, where the compound was developed. The authors report a route of 6 steps with a 51% overall yield that avoids expensive iridium and palladium catalysts and doesn't require chromatographic purification, which they describe as overcoming the main limitations of the earlier method. The paper discloses that the university holds a related patent, YourChoice holds the exclusive license, and Dr. Georg consults for the company.

Chemistry papers don't tell us whether a drug works. But a simpler, cheaper, scalable manufacturing route is the kind of groundwork needed before larger trials and any eventual commercial supply.

How to read what comes next

When sperm data does appear, WHO's new benchmarks give a useful frame: for sperm-suppression methods, WHO's minimum target is 90% of men reaching 1 million sperm/mL or less within 12 weeks. We explain those standards in our WHO guide. A small open-label study can't answer the pregnancy-prevention question on its own; that requires larger trials.

Why this trial matters so much

YCT-529 gets outsized attention because it would be a daily pill that doesn't use hormones, which many people see as the most familiar and least disruptive form a male method could take. The Phase 1b/2a study is the first time the program will publicly show whether daily dosing lowers sperm production in men, how quickly, and whether counts recover after stopping. Those are the questions any eventual Phase 3 trial and regulator would ask. Until those numbers are published, claims that the male pill is "almost here" go beyond the evidence. That's also why we compare it with other candidates on the status page: NES/T gel, for example, has completed a larger Phase 2b study, while YCT-529 is earlier in development.

What to watch

An update to NCT06542237 (new dates, a status change or posted results).
A conference abstract or paper with sperm-count data.
Any announcement about a larger, placebo-controlled trial.

We check the registry regularly; see the status page for the latest.

Get the next update

We follow these programs from registries, journals and developers, and we'll email when something real changes: trial results, new studies, regulatory filings. It's free and it's not a preorder. Join the update list.

This article is news and education, not medical advice. No male contraceptive described here is approved. Get notified of updates.